Document Detail


Anti-vascular endothelial growth factor antibody and nimustine as combined therapy: effects on tumour growth and angiogenesis in human glioblastoma xenografts.
MedLine Citation:
PMID:  12626127     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We evaluated the effectiveness of vascular endothelial growth factor (VEGF) blockade alone and in combination with 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU, nimustine), a cytotoxic agent commonly used in the treatment of malignant gliomas, to eradicate tumors of human glioblastoma cell lines implanted in SCID (severe combined immunodeficiency) mice. ACNU, but not cisplatin and etoposide, elevated VEGF expression in a glioma cell line in vitro. VEGF antibody alone inhibited glioma growth in vivo as a result of angiogenesis inhibition. The combination with ACNU resulted in an additive effect for inhibition of glioma growth. ACNU also induced VEGF up-regulation in glioma tissues, which was decreased with VEGF antibody treatment. One of the mechanisms of the additive effect of the VEGF antibody and ACNU combination is the blockade of VEGF up-regulation induced by ACNU. As such, the combination of antiangiogenic therapy with conventional therapy is promising for glioma treatment in the future.
Authors:
Shingo Takano; Koji Tsuboi; Akira Matsumura; Tadao Nose
Related Documents :
17273757 - A novel breast cancer cell line initially established from pleural effusion: evolution ...
12368197 - Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in mali...
7707437 - Expression of vascular endothelial growth factor and its receptors flt and kdr in ovari...
11169947 - Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth f...
12417717 - Biallelic mutations in p16(ink4a) confer resistance to ras- and ets-induced senescence ...
22451897 - Molecular mri enables early and sensitive detection of brain metastases.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neuro-oncology     Volume:  5     ISSN:  1522-8517     ISO Abbreviation:  Neuro-oncology     Publication Date:  2003 Jan 
Date Detail:
Created Date:  2003-03-10     Completed Date:  2003-06-11     Revised Date:  2008-11-20    
Medline Journal Info:
Nlm Unique ID:  100887420     Medline TA:  Neuro Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1-7     Citation Subset:  IM    
Affiliation:
Department of Neurosurgery, Institute of Clinical Medicine, University of Tsukuba, 1-1-1 Tennoudai, Ibaraki 305-8575, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antibodies / administration & dosage,  therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Endothelial Growth Factors / antagonists & inhibitors*,  biosynthesis,  immunology*
Glioblastoma / drug therapy*,  metabolism
Humans
Intercellular Signaling Peptides and Proteins / biosynthesis,  immunology*
Lymphokines / antagonists & inhibitors*,  biosynthesis,  immunology*
Male
Mice
Mice, SCID
Neoplasm Transplantation
Neovascularization, Pathologic / drug therapy*
Nimustine / administration & dosage*,  therapeutic use*
Tumor Cells, Cultured
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Xenograft Model Antitumor Assays / methods
Chemical
Reg. No./Substance:
0/Antibodies; 0/Endothelial Growth Factors; 0/Intercellular Signaling Peptides and Proteins; 0/Lymphokines; 0/Vascular Endothelial Growth Factor A; 0/Vascular Endothelial Growth Factors; 42471-28-3/Nimustine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice.
Next Document:  A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of...